Sources
Story Timeline
•Latest version
GSK Raises Annual Forecasts on Strong Arexvy Sales, Quarterly Sales of $862 Million, Expects 12% to 13% Growth
GSK's RSV Vaccine Shows Promise, Raises Profit Forecasts Amid Pfizer Competition
GSK's RSV Vaccine Shows Promise in Adults Aged 50-59, Raises Profit Forecasts with Better-than-Expected Sales
GSK's RSV Vaccine Shows Promise in Adults 50-59, Pfizer Lags Behind in Head-to-Head Competition
•Original version
GSK's RSV Vaccine Shows Potential in Adults 50-59, Pfizer Lags Behind in Head-to-Head Competition
